Analysis of the main targets and mechanism of action of Telisotuzumab

Telisotuzumab (Telisotuzumab) is an innovative humanized monoclonal antibody that mainly targets the hepatocyte growth factor receptor (c-Met, also known as HGFR, hepatocyte growth factor receptor). c-Met Abnormally high expression or gene amplification occurs on the surface of various solid tumor cells, promoting tumor growth, invasion and metastasis, and therefore becoming an important target for anti-tumor treatment. Terituzumab binds to c-Met with high affinity and blocks its binding to hepatocyte growth factor (HGF), thereby inhibiting the activation of downstream signaling pathways.

The c-Met signaling pathway in tumor cells mainly regulates cell proliferation, survival, migration and angiogenesis by activating key pathways such as PI3K/AKT and RAS/MAPK. Terituzumab blocks the activation of c-Met receptors, inhibits these signaling pathways, prevents the proliferation and metastasis of tumor cells, and promotes the apoptosis of tumor cells. In addition, terituzumab can also enhance the immune system's ability to clear tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC).

The antibody not only works alone, but also has the potential to be used in combination with chemotherapy drugs or other targeted drugs to further enhance the anti-tumor effect. Clinical studies have shown that terituzumab exhibits good anti-tumor activity and safety in patients with c-Met-positive tumors such as non-small cell lung cancer (NSCLC), providing a new treatment option for such patients.

In short, terituzumab can inhibit the growth and metastasis of tumor cells by specifically targeting and blocking the c-Met receptor and its downstream signaling pathways, while activating the anti-tumor effect mediated by the immune system, making it a powerful weapon in the treatment of c-Met-driven solid tumors. With the deepening of clinical research, its application prospects in precision tumor treatment are broad.

Reference materials:https://www.drugs.com/

xa0